The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care

M Ellen Kuenzig, Lawrence Lee, Wael El-Matary, Adam V Weizman, Eric I Benchimol, Gilaad G Kaplan, Geoffrey C Nguyen, Charles N Bernstein, Alain Bitton, Kate Lee, Jane Cooke-Lauder, Sanjay K Murthy, M Ellen Kuenzig, Lawrence Lee, Wael El-Matary, Adam V Weizman, Eric I Benchimol, Gilaad G Kaplan, Geoffrey C Nguyen, Charles N Bernstein, Alain Bitton, Kate Lee, Jane Cooke-Lauder, Sanjay K Murthy

Abstract

The indirect cost of illness represents the portion of human capital that is foregone due to lost productivity of patients and their caregivers and out-of-pocket healthcare expenses borne directly by patients. Indirect costs among persons with inflammatory bowel diseases (IBD) may be substantial because disease onset occurs during the teens and 20s for most persons and is lifelong. Thus, most persons with IBD are affected during periods of study or employment. The literature on indirect health-related costs among persons with IBD is limited, particularly with regard to Canadian studies. The greatest burden of indirect costs in this population relates to absenteeism and presenteeism among working individuals and premature retirement. However, costs related to reduced professional development and personal achievement due to illness-as well as caregiver costs-are largely unknown. After being extrapolated from multiple sources, the total indirect health-related cost of IBD in Canada in 2018 is estimated to be $1.29 billion Canadian dollars. Notably, this may be a significant underestimate because costs relating to presenteeism, reduced achievement and caregiver burden could not be estimated and are excluded from this calculation.

Highlights: Indirect costs account for a major portion of total healthcare costs among persons with inflammatory bowel disease (IBD) and are higher than indirect costs among persons without IBD.Persons with IBD are more likely to require time off work (absenteeism) and have reduced productivity at work (presenteeism) due to illness as compared with persons without IBD.Premature retirement and long-term disability are major factors contributing to indirect costs among IBD patients.A substantial proportion of individuals with IBD pay out-of-pocket for complementary and alternative medicines.After being extrapolated from multiple sources, the total annual indirect cost of IBD in Canada is estimated to be $1.29 billion CAD in 2018, or $4781 CAD per person with IBD.

Key summary points: The total indirect economic burden of IBD in Canada is estimated to be $1.29 billion CAD in 2018, or roughly $4781 CAD per person with IBD. This estimate comprises lost wages related to sick days and disability, premature retirement and premature death, and out-of-pocket costs. Losses from presenteeism, reduced professional development and caregiver burden are not included due to insufficient data on the cost impact of these factors.In a meta-analysis of studies between 1994 and 2014, the annual indirect cost of absenteeism for IBD patients ranged from $515.67 USD (USA) to $14,727 USD (Germany) per patient per annum (pooled estimate $7189 USD), after adjusting for purchasing power disparity.A large US survey found that, on average, IBD patients incurred an extra 4.8 days off of work and $783 USD in excess lost wages annually compared with persons without IBD.A study based on US private insurance claims found that ulcerative colitis patients cost an additional $2164 per person per annum relating to disability days and medically related absenteeism.A prospective study from an IBD centre reported weekly indirect health-related costs of $1133 for IBD patients with active disease, $370.13 for IBD patients in remission, and $191.23 for persons without IBD relating to both presenteeism and absenteeism.In a survey of 744 IBD patients from Manitoba, reduced workplace productivity during the previous 14 days was reported in 37% of individuals, including a reduction of one to two days by 18% of patients, thre to nine days by 16% of patients, and on most days by 3% of patients.The estimated average lifetime lost wages due to premature retirement is $1,044,498 CAD per person with Crohn's disease and $994,760 CAD per person with ulcerative colitis. Aggregated over all IBD retirees, this equates to roughly $629 million CAD in permanent lost wages annually due to premature retirement.The lifetime indirect cost associated with premature death among IBD patients is estimated to be $746,070 CAD per decedent, or roughly $33.6 million aggregated across all IBD decedents of working age.In a US study of caregivers of children, the average unadjusted annual work loss was 214 hours for caregivers of Crohn's disease patients and 170 hours for caregivers of children without IBD, translating to an additional $1122 in lost productivity for caregivers of persons with Crohn's disease.Canadian studies have reported complementary and alternative medicines (CAMs) use in 56% to 74% of people with IBD. A US national survey study estimated annual per-person out of pocket costs of $1603 USD for Crohn's disease patients and $1263 USD for ulcerative colitis patients, which were substantially higher than in persons without IBD.

Gaps in knowledge and future directions: Canadian-specific data on indirect health-related costs of IBD is sparse across all domains of indirect costs.In particular, the rates of absenteeism, presenteeism and premature retirement among IBD patients living in Canada require further study to gauge more accurately the indirect health-related costs of IBD in Canada.Indirect costs relating to decreased professional development, caregiver burden and out-of-pocket purchases among IBD patients are largely unknown and require further study.Indirect costs incurred by Canadian children with IBD and their families or caregivers are largely unknown.

Keywords: Costs; Crohn’s disease; Inflammatory bowel disease; Prevalence; Quality of life; Ulcerative colitis.

Figures

Figure 1.
Figure 1.
Prevalence of absenteeism, presenteeism and activity impairment in controls and patients with IBD with active and inactive disease. *P < 0.01, **P < 0.01, ***P < 0.01, +P = 0.02 (23) (reprinted with permission)
Figure 2.
Figure 2.
Indirect costs as a percentage of maximum weekly compensation for employees. *P < 0.01, **P < 0.01, ***P < 0.01, +P = 0.02, ++P < 0.03 (23) (reprinted with permission)

References

    1. Kawalec P, Malinowski KP. Indirect health costs in ulcerative colitis and Crohn’s disease: A systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015;15(2):253–66.
    1. Cohen R, Rizzo J, Yang M, et al. . Direct and indirect utilization and costs associated with ulcerative colitis. Am J Gastroenterol 2012;107.
    1. Gibson TB, Ng E, Ozminkowski RJ, et al. . The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med 2008;50(11):1261–72.
    1. Hay JW, Hay AR. Inflammatory bowel disease: Costs-of-illness. J Clin Gastroenterol 1992;14(4):309–17.
    1. Lofland J, Naim A, Rizzo J, et al. . The indirect costs of inflammatory bowel disease: Evidence from United States National Survey Data. Gastroenterology 2010;138(5).
    1. Loftus EV Jr, Guerin A, Tsaneva M, et al. . Direct and indirect economic burdens and impact on salary growth of moderate to severe Crohn’s disease. Gastroenterology 2009;136(5):A26–7.
    1. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey. Am J Gastroenterol 2003;98(5):1064–72.
    1. Longobardi T, Jacobs P, Wu L, et al. . Work losses related to inflammatory bowel disease in Canada: Results from a National Population Health Survey. Am J Gastroenterol 2003;98(4):844–9.
    1. Naim A, Nair K, Van Den Bos J, et al. . Comparison of total health care expenditures and absenteeism for inflammatory bowel disease from an employer’s perspective. Value Health 2010;13(3):A207.
    1. Sandborn W, Colombel JF, Louis E, et al. . Economic impact of deep remission in adalimumab-treated patients with Crohn’s disease: Results from extend. Gastroenterology 2011;140(5):S205.
    1. Bassi A, Dodd S, Williamson P, et al. . Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study. Gut 2004;53(10):1471–8.
    1. Benedini V, Caporaso N, Corazza GR, et al. . Burden of Crohn’s disease: Economics and quality of life aspects in Italy. Clinicoecon Outcomes Res 2012;4:209–18.
    1. Blomqvist P, Ekbom A. Inflammatory bowel diseases: Health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32(11):1134–9.
    1. Juan J, Estiarte R, Colome E, et al. . Burden of illness of Crohn’s disease in Spain. Dig Liver Dis 2003;35(12):853–61.
    1. Mandel MD, Balint A, Lovasz BD, et al. . Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014;15(Suppl 1):S121–8.
    1. Mesterton J, Jonsson L, Almer S, et al. . Resource use and societal costs for Crohn’s disease in Sweden. Inflamm Bowel Dis 2009;15(12):1882–90.
    1. Stark R, Konig H, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24(8):797–814.
    1. van der Valk ME, Mangen MJ, Leenders M, et al. . Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: Results from the COIN study. Gut 2014;63(1):72–9.
    1. Lion M, Gearry R, Day A, et al. . The cost of paediatric and perianal Crohn’s disease in Canterbury, New Zealand. N Z Med J 2012;125(1349):11–20.
    1. Australian Crohn’s and Colitis Association. The Economic Costs of Crohn’s Disease and Ulcerative Colitis. 2017.
    1. Gunnarsson C, Chen J, Rizzo J, et al. . The employee absenteeism costs of inflammatory bowel disease: Evidence from US National Survey Data. J Occup Environ Med 2013;55(4):393–401.
    1. Cohen R, Skup M, Ozbay AB, et al. . Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ 2015;18(6):447–56.
    1. Zand A, van Deen W, Inserra E, et al. . Presenteeism in Inflammatory Bowel Diseases: A hidden problem with significant economic impact. Inflamm Bowel Dis 2015;21(7):1623–30.
    1. Berger M, Murray J, Xu J, et al. . Alternative valuations of work loss and productivity. J Occup Environ Med 2001;43(1):18–24.
    1. Shafer LA, Walker JR, Restall G, et al. . Association between IBD disability and reduced work productivity (Presenteeism): A population-based study in Manitoba, Canada. Inflamm Bowel Dis 2018.
    1. Chhibba T, Walker JR, Sexton K, et al. . Workplace accommodation for persons with IBD: What is needed and what is accessed. Clin Gastroenterol H 2017;15(10):1589–95.
    1. Statistics Canada. Average weekly earnings (including overtime), by province and territory. 2017.
    1. Coward S, Clement F, Benchimol Eric I, et al. . The rising prevalence of inflammatory bowel disease in Canada: Analyzing the past to predict the future. JCAG 2018;1(Suppl 2):A-29.
    1. Busch K, da Silva SA, Holton M, et al. . Sick leave and disability pension in inflammatory bowel disease: A systematic review. J Crohns Colitis 2014;8(11):1362–77.
    1. Boonen A, Dagnelie PC, Feleus A, et al. . The impact of inflammatory bowel disease on labor force participation: Results of a population sampled case-control study. Inflamm Bowel Dis 2002;8(6):382–9.
    1. Nurmi E, Haapamaki J, Paavilainen E, et al. . The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol 2013;48(1):51–7.
    1. Stallmach A, Dennler U, Marschall U, et al. . Patient-relevant endpoints in inflammatory bowel diseases—have changes occurred in Germany over the past twelve years?J Crohns Colitis 2015;9(5):390–7.
    1. Statistics Canada. Table 282-0051: Labour Fource Survey Estimates, Retirement Age by Class of Worker and Sex. 2018.
    1. Trading Economics. Germany retirement age—men. 2018.
    1. Trading Economics. Germany retirement age—women. 2018.
    1. Bernstein CN, Nugent Z, Targownik LE, et al. . Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut 2015;64(9):1403–11.
    1. Nguyen GC, Bernstein CN, Benchimol EI. Risk of surgery and mortality in elderly-onset inflammatory bowel disease: a population-based cohort study. Inflamm Bowel Dis 2017;23(2):218–23.
    1. Statistics Canada. Table 102–0531--Deaths, by cause, Chapter XI: Diseases of the digestive system (K00 to K93), age group and sex, Canada, Annual. 2017.
    1. Rocchi A, Benchimol EI, Bernstein CN, et al. . Inflammatory bowel disease: A Canadian burden of illness review. Can J Gastroenterol 2012;26(11):811–7.
    1. Singh H, Nugent Z, Brownell M, et al. . Academic performance among children with inflammatory bowel disease: A population-based study. J Pediatr 2015;166(5):1128–33.
    1. Adler J, Raju S, Beveridge AS, et al. . College adjustment in University of Michigan students with Crohn’s and colitis. Inflamm Bowel Dis 2008;14(9):1281–6.
    1. Feagan BG, Bala M, Yan S, et al. . Unemployment and disability in patients with moderately to severely active Crohn’s disease. J Clin Gastroenterol 2005;39(5):390–5.
    1. Loftus EV Jr, Skup M, Ozbay AB, et al. . The impact of moderate-to-severe Crohn’s disease on employees’ salary growth. Inflamm Bowel Dis 2014;20(10):1734–8.
    1. Kahn SA, Lin CW, Ozbay B, et al. . Indirect costs and family burden of pediatric Crohn’s disease in the United States. Inflamm Bowel Dis 2017;23(12):2089–96.
    1. Gunnarsson C, Chen J, Rizzo JA, et al. . Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: Evidence from a US national survey. Dig Dis Sci 2012;57(12):3080–91.
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. . Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135(6):1907–13.
    1. Hilsden RJ, Verhoef MJ, Rasmussen H, et al. . Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17(2):655–62.
    1. Rawsthorne P, Clara I, Graff LA, et al. . The Manitoba Inflammatory Bowel Disease Cohort Study: A prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut 2012;61(4):521–7.
    1. Zollman C, Vickers A. What is complementary medicine?BMJ 1999;319(7211):693–6.
    1. Nguyen G, Croitoru K, Silverberg MS, et al. . Use of complementary and alternative medicine for inflammatory bowel disease is associated with worse adherence to conventional therapy: The COMPLIANT study. Inflamm Bowel Dis 2016;22(6):1412–7.
    1. Weizman AV, Ahn E, Thanabalan R, et al. . Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35(3):342–9.
    1. Abitbol V, Lahmek P, Buisson A, et al. . Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: Results from a French national survey. Eur J Gastroenterol Hepatol 2014;26(3):288–94.
    1. Opheim R, Bernklev T, Fagermoen MS, et al. . Use of complementary and alternative medicine in patients with inflammatory bowel disease: Results of a cross-sectional study in Norway. Scand J Gastroenterol 2012;47(12):1436–47.
    1. Park D, Cha J, Kim H, et al. . Predictive factors of complementary and alternative medicine use for patients with inflammatory bowel disease in Korea. Complement Ther Med 2013;22(1):87–93.
    1. Becker HM, Grigat D, Ghosh S, et al. . Living with inflammatory bowel disease: A Crohn’s and Colitis Canada survey. Can J Gastroenterol Hepatol 2015;29(2):77–84.
    1. Sin A, Damman J, Ziring D, et al. . Out-of-pocket cost burden in pediatric inflammatory bowel disease: A cross-sectional cohort analysis. Inflamm Bowel Dis 2015;21(6):1368–77.
    1. Dziechciarz P, Horvath A, Shamir R, et al. . Meta-analysis: Enteral nutrition in active Crohn’s disease in children. Aliment Pharmacol Ther 2007;26(6):795–806.

Source: PubMed

3
订阅